Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension

BACKGROUND: Despite the increased risk for pulmonary hypertension in children with Down syndrome, the response to treatment with targeted therapies for pulmonary hypertension in these patients is not well characterized. The Sildenafil in Treatment-naive children, Aged 1–17 years, with pulmonary arte...

Descripción completa

Detalles Bibliográficos
Autores principales: Beghetti, Maurice, Rudzinski, Andrzej, Zhang, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496590/
https://www.ncbi.nlm.nih.gov/pubmed/28676038
http://dx.doi.org/10.1186/s12872-017-0569-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496590/
https://www.ncbi.nlm.nih.gov/pubmed/28676038
http://dx.doi.org/10.1186/s12872-017-0569-3

Ejemplares similares